Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy’s safety profile
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy’s safety profile
Authors
Keywords
-
Journal
POSTGRADUATE MEDICINE
Volume 128, Issue 6, Pages 609-619
Publisher
Informa UK Limited
Online
2016-05-23
DOI
10.1080/00325481.2016.1191955
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell–Centric Classification Schema
- (2016) Stanley S. Schwartz et al. DIABETES CARE
- Pioglitazone (Actos) and bladder cancer: Legal system triumphs over the evidence
- (2016) Mayer B. Davidson JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Accelerated protein digestion and amino acid absorption after Roux-en-Y gastric bypass
- (2015) Kirstine N Bojsen-Møller et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
- (2015) Silvio E Inzucchi et al. Diabetes & Vascular Disease Research
- Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)
- (2015) Nikolaus Marx et al. Diabetes & Vascular Disease Research
- Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
- (2015) M. A. Abdul-Ghani et al. DIABETES OBESITY & METABOLISM
- One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial
- (2015) S. C. L. Gough et al. DIABETES OBESITY & METABOLISM
- Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial
- (2015) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2015) Silvio E. Inzucchi et al. DIABETOLOGIA
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY – CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN – 2015 —EXECUTIVE SUMMARY
- (2015) Yehuda Handelsman et al. Endocrine Practice
- AACE/ACE COMPREHENSIVE DIABETES MANAGEMENT ALGORITHM 2015
- (2015) Alan J. Garber et al. Endocrine Practice
- Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes
- (2015) James D. Lewis et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-term Mortality
- (2015) Trevor J. Orchard et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
- (2015) Faiez Zannad et al. LANCET
- Inflammation and Oxidative Stress: The Molecular Connectivity between Insulin Resistance, Obesity, and Alzheimer’s Disease
- (2015) Giuseppe Verdile et al. MEDIATORS OF INFLAMMATION
- Editorial: Rethinking the Definition of Diabetes for Precision Medicine
- (2015) Rexford S. Ahima MOLECULAR ENDOCRINOLOGY
- Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Rodney A. Hayward et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality
- (2015) Emily Jane Gallagher et al. PHYSIOLOGICAL REVIEWS
- Revisiting weight reduction and management in the diabetic patient: Novel therapies provide new strategies
- (2015) Stanley Schwartz et al. POSTGRADUATE MEDICINE
- Insulin administration: present strategies and future directions for a noninvasive (possibly more physiological) delivery
- (2015) Elena Matteucci et al. Drug Design Development and Therapy
- Nitric oxide and mitochondria in metabolic syndrome
- (2015) Larisa Litvinova et al. Frontiers in Physiology
- On the potential of acarbose to reduce cardiovascular disease
- (2014) Eberhard Standl et al. Cardiovascular Diabetology
- Incretin-Based Therapies, Glucometabolic Health and Endovascular Inflammation
- (2014) Manfredi Rizzo et al. CURRENT PHARMACEUTICAL DESIGN
- Is there U-turn from Insulin Back to Pills in Diabetes?
- (2014) Sibel Ertek et al. Current Vascular Pharmacology
- Insulin Action in Brain Regulates Systemic Metabolism and Brain Function
- (2014) A. Kleinridders et al. DIABETES
- Repurposing Diabetes Drugs for Brain Insulin Resistance in Alzheimer Disease
- (2014) M. Yarchoan et al. DIABETES
- Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer
- (2014) S. E. Holden et al. DIABETES OBESITY & METABOLISM
- New Treatments for Type 2 Diabetes: Cardiovascular Protection Beyond Glucose Lowering?
- (2014) Dilshani Jayawardene et al. Heart Lung and Circulation
- Exposure to excess insulin (glargine) induces type 2 diabetes mellitus in mice fed on a chow diet
- (2014) Xuefeng Yang et al. JOURNAL OF ENDOCRINOLOGY
- Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis
- (2014) Conrad Eng et al. LANCET
- Evidence-Based Practice Use of Incretin-Based Therapy in the Natural History of Diabetes
- (2014) Stanley Schwartz POSTGRADUATE MEDICINE
- Hyperinsulinemic syndrome: The metabolic syndrome is broader than you think
- (2014) Christopher T. Kelly et al. SURGERY
- Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial
- (2013) Steven P. Marso et al. AMERICAN HEART JOURNAL
- Glycemic Control in Type 2 Diabetes: Time for an Evidence-Based About-Face?
- (2013) Victor M. Montori ANNALS OF INTERNAL MEDICINE
- Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes
- (2013) John B. Buse et al. ANNALS OF INTERNAL MEDICINE
- Individualizing Glycemic Targets in Type 2 Diabetes Mellitus: Implications of Recent Clinical Trials
- (2013) Faramarz Ismail-Beigi et al. ANNALS OF INTERNAL MEDICINE
- Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin
- (2013) John P.H. Wilding ANNALS OF INTERNAL MEDICINE
- The Injurious Effects of Hyperinsulinism on Blood Vessels
- (2013) Xukai Wang et al. CELL BIOCHEMISTRY AND BIOPHYSICS
- Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
- (2013) Jonathan E. Campbell et al. Cell Metabolism
- Prevention of Diabetes With Pioglitazone in ACT NOW: Physiologic Correlates
- (2013) R. A. DeFronzo et al. DIABETES
- Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin
- (2013) Matthew C. Riddle et al. DIABETES CARE
- Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyperglycemic Therapies in Type 2 Diabetes
- (2013) Craig J. Currie et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials
- (2013) Denis Raccah et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intensive insulin for type 2 diabetes: the risk of causing harm
- (2013) Christopher J Nolan et al. Lancet Diabetes & Endocrinology
- Endogenous hyperinsulinaemia and exogenous insulin: A common theme between atherosclerosis, increased cancer risk and other morbidities
- (2012) Sarah E. Holden et al. ATHEROSCLEROSIS
- Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
- (2012) Michael E Cobble et al. Cardiovascular Diabetology
- Cardiovascular Biology of the Incretin System
- (2012) John R. Ussher et al. ENDOCRINE REVIEWS
- Effects of Bariatric Surgery on Glucose Homeostasis and Type 2 Diabetes
- (2012) David Bradley et al. GASTROENTEROLOGY
- Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
- (2012) Alan J Garber et al. LANCET
- Focusing on Cardiovascular Disease in Type 2 Diabetes Mellitus: An Introduction to Bromocriptine QR
- (2012) David S. H. Bell POSTGRADUATE MEDICINE
- Insulin Resistance: Pathophysiology and Rationale for Treatment
- (2011) Sergio Muntoni et al. ANNALS OF NUTRITION AND METABOLISM
- Insulin resistance: from bit player to centre stage
- (2011) G. M. Reaven CANADIAN MEDICAL ASSOCIATION JOURNAL
- Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
- (2011) Robert Ratner et al. Cardiovascular Diabetology
- Vasculotoxic Effects of Insulin and Its Role in Atherosclerosis: What is the Evidence?
- (2011) Shailesh Nandish et al. Current Atherosclerosis Reports
- Insulin: Potential Negative Consequences of Early Routine Use in Patients With Type 2 Diabetes
- (2011) H. E. Lebovitz DIABETES CARE
- Effects of Exenatide on Measures of -Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes
- (2011) M. C. Bunck et al. DIABETES CARE
- The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern
- (2011) C. J. Currie et al. DIABETES OBESITY & METABOLISM
- The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
- (2011) R. A. DeFronzo et al. DIABETES OBESITY & METABOLISM
- Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin–Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study
- (2011) L. G. Mellbin et al. DIABETOLOGIA
- Successful Treatment of Prediabetes in Clinical Practice: Targeting Insulin Resistance and β-Cell Dysfunction
- (2011) John Armato et al. Endocrine Practice
- One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial
- (2011) R. Pratley et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Focus on Incretin-Based Therapies: Targeting the Core Defects of Type 2 Diabetes
- (2011) Paul S. Jellinger POSTGRADUATE MEDICINE
- Mechanism of the mitogenic influence of hyperinsulinemia
- (2011) Boris Draznin Diabetology & Metabolic Syndrome
- Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin: A proof-of-concept study
- (2010) S. Arnolds et al. DIABETES CARE
- A1C and Cardiovascular Outcomes in Type 2 Diabetes: A nested case-control study
- (2010) D. C. Colayco et al. DIABETES CARE
- Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes
- (2010) J. Rosenstock et al. DIABETES CARE
- Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD Trial
- (2010) M. C. Riddle et al. DIABETES CARE
- Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies: A retrospective analysis of the LifeLink database
- (2010) J. H. Best et al. DIABETES CARE
- Intensified glucose lowering in type 2 diabetes: time for a reappraisal
- (2010) J. S. Yudkin et al. DIABETOLOGIA
- Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study
- (2010) Craig J Currie et al. LANCET
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
- (2009) R. A. DeFronzo DIABETES
- Early Insulin Use in Type 2 Diabetes: What are the cons?
- (2009) J.-L. Chiasson DIABETES CARE
- Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial
- (2009) M. Jadzinsky et al. DIABETES OBESITY & METABOLISM
- Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies
- (2009) S. Del Prato DIABETIC MEDICINE
- Mitogenic action of insulin: friend, foe or ‘frenemy’?
- (2009) B. Draznin DIABETOLOGIA
- Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
- (2009) Arne Astrup et al. LANCET
- Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association
- (2008) J. S. Skyler et al. DIABETES CARE
- Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes
- (2008) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes
- (2008) Kenji Nonaka et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial
- (2008) Jianping Weng et al. LANCET
- Paget's Disease of the Mandible
- (2008) Mayank B. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
- (2008) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
- (2008) William Duckworth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association between serious ischemic cardiac outcomes and medications used to treat diabetes
- (2008) David J. Margolis et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started